Research progress of integrin-targeted radiopharmaceuticals in tumor diagnosis and treatment
10.3760/cma.j.cn321828-20240204-00053
- VernacularTitle:靶向整合素的放射性药物在肿瘤诊疗中的研究进展
- Author:
Guangjie YANG
1
;
Li HUO
1
Author Information
1. 中国医学科学院、北京协和医学院北京协和医院核医学科、核医学分子靶向诊疗北京市重点实验室，北京 100730
- Publication Type:Journal Article
- Keywords:
Neoplasms;
Radiopharmaceuticals;
Integrins;
Trends
- From:
Chinese Journal of Nuclear Medicine and Molecular Imaging
2025;45(2):114-119
- CountryChina
- Language:Chinese
-
Abstract:
Integrin is a kind of transmembrane glycoprotein, which is highly expressed in tumor neovascular endothelial cells and various tumor cells, but lowly or negatively expressed in normal tissues. Integrin-targeted diagnostic or therapeutic radiopharmaceuticals can non-invasively display tumor characteristics in vivo, evaluate angiogenesis and perform targeted radiotherapy for tumors, which have great clinical application value. This article reviews the research progress of radiopharmaceuticals targeting integrins in tumor diagnosis and treatment.
